Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

Diabetes is a chronic, progressively worsening disease associated with a variety of microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main cause of death in these patients.1,2 During the past decade, numerous drugs have been introduced for the treatment of type 2 diabetes that, used in monotherapy or in combination therapy, are effective in lowering blood glucose to achieve glycemic goals and in reducing diabetes-related end-organ disease. Two such drugs, rosiglitazone and pioglitazone, belong to the class called thiazolidinediones (TZDs).3 Troglitazone, the first agent of this class to be approved, was effective in controlling glycemia but was removed from the market because of serious liver toxicity. Both rosiglitazone and pioglitazone are indicated either as monotherapy or in combination with a sulfonylurea, metformin, or insulin when diet, exercise, and a single agent do not result in adequate glycemic control4 (package insert Avandia [rosiglitazone maleate; GlaxoSmithKline] and Actos5 [pioglitazone hydrochloride; Takeda Pharmaceuticals]). In addition to lowering blood glucose, both drugs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function, and fibrinolytic status.6,7 These beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them attractive agents in patients with type 2 diabetes who are at high risk for CVD. There is a growing recognition, however, that edema can occur in patients treated with either drug. Because people with diabetes are at increased risk for CVD and many have preexisting heart disease, the edema that sometimes accompanies the use of a TZD can be cause for concern, as it may be a harbinger or sign of congestive heart failure (CHF). An analysis of Medicare beneficiaries hospitalized with the diagnosis of diabetes and CHF indicated that the number of these patients discharged on TZDs had increased from 7.2% to 16.2% over a …

[1]  T. Rea,et al.  Consent in resuscitation trials: benefit or harm for patients and society? , 2006, Resuscitation.

[2]  M. Holzer,et al.  Global hypothermia for neuroprotection after cardiac arrest , 2006, Acute cardiac care.

[3]  B. Mourvillier,et al.  Predicting survival with good neurological recovery at hospital admission after successful resuscitation of out-of-hospital cardiac arrest: the OHCA score. , 2006, European heart journal.

[4]  Philip J Podrid,et al.  Epidemiology and stratification of risk for sudden cardiac death , 2005, Clinical cardiology.

[5]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[6]  K. Sunnerhagen,et al.  The first year after successful cardiac resuscitation: function, activity, participation and quality of life. , 2005, Resuscitation.

[7]  F. Gómez-Jiménez,et al.  Reversible myocardial dysfunction after cardiopulmonary resuscitation. , 2005, Resuscitation.

[8]  Andrew R Willan,et al.  The value of information and optimal clinical trial design , 2005, Statistics in medicine.

[9]  B. Hindman,et al.  Mild Intraoperative Hypothermia During Surgery for Intracranial Aneurysm , 2005 .

[10]  H. Nguyen,et al.  Bench-to-bedside review: Outcome predictions for critically ill patients in the emergency department , 2005, Critical care.

[11]  J. Timsit,et al.  Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. , 2005, Journal of critical care.

[12]  B. Schmand,et al.  Cognitive impairment in survivors of out-of-hospital cardiac arrest. , 2004, American heart journal.

[13]  R. Bellomo,et al.  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.

[14]  L. Lind,et al.  Rapid Emergency Medicine score: a new prognostic tool for in‐hospital mortality in nonsurgical emergency department patients , 2004, Journal of internal medicine.

[15]  R. Berg,et al.  A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. , 2004, The New England journal of medicine.

[16]  D. Bell Thiazolidinedione-associated congestive heart failure and pulmonary edema. , 2004, Mayo Clinic proceedings.

[17]  V. Pettilä,et al.  Serum Neuron-Specific Enolase and S-100B Protein in Cardiac Arrest Patients Treated With Hypothermia , 2003, Stroke.

[18]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[19]  I. Stiell,et al.  Health-Related Quality of Life Is Better for Cardiac Arrest Survivors Who Received Citizen Cardiopulmonary Resuscitation , 2003, Circulation.

[20]  J. Ornato,et al.  Cardiopulmonary resuscitation of adults in the hospital: a report of 14720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. , 2003, Resuscitation.

[21]  H. Krumholz,et al.  Metformin and thiazolidinedione use in Medicare patients with heart failure. , 2003, JAMA.

[22]  A. Hart,et al.  A prospective, randomised and blinded comparison of first shock success of monophasic and biphasic waveforms in out-of-hospital cardiac arrest. , 2003, Resuscitation.

[23]  W. Landau,et al.  Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest , 2003, Neurology.

[24]  B. Hoogwerf,et al.  Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. , 2003, Journal of the American College of Cardiology.

[25]  P. Steen,et al.  Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. , 2003, JAMA.

[26]  T. Marwick,et al.  Echocardiographic detection of early diabetic myocardial disease. , 2003, Journal of the American College of Cardiology.

[27]  A. Takeshita,et al.  Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[28]  K. Murphy,et al.  A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. , 2002, Diabetes care.

[29]  Bramahn . Singh Amiodarone compared with lidocaine for shock-resistant ventricular fibrillation , 2002, Current cardiology reports.

[30]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[31]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[32]  J. Cavaillon,et al.  Successful Cardiopulmonary Resuscitation After Cardiac Arrest as a “Sepsis-Like” Syndrome , 2002, Circulation.

[33]  Nancee V. Niemeyer,et al.  Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.

[34]  Karen Smith,et al.  Treatment of Comatose Survivors of Out-of-hospital Cardiac Arrest With Induced Hypothermia , 2003 .

[35]  J. Hardies,et al.  Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.

[36]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[37]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[38]  D. Chyun,et al.  Heart disease in patients with diabetes , 2002 .

[39]  Cunegundo M Vergara,et al.  Management of rosiglitazone-induced edema: two case reports and a review of the literature. , 2002, Diabetes technology & therapeutics.

[40]  Shaun Cho,et al.  Peripheral edema. , 2002, The American journal of medicine.

[41]  J. M. Quesada-Gomez,et al.  Nonhypoglycemic effects of thiazolidinediones. , 2001, Annals of internal medicine.

[42]  S. Kihara,et al.  Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. , 2001, Diabetes research and clinical practice.

[43]  S. Stratton,et al.  Outcome of out-of-hospital postcountershock asystole and pulseless electrical activity versus primary asystole and pulseless electrical activity , 2001, Critical care medicine.

[44]  W. Bao,et al.  In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone , 2001, Circulation.

[45]  P. Tappenden,et al.  A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. , 2001, Clinical therapeutics.

[46]  A. Hijdra,et al.  Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage , 2001, Intensive Care Medicine.

[47]  J. Fink,et al.  Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. , 2001, American journal of hypertension.

[48]  G. Nichols,et al.  Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. , 2001, Diabetes care.

[49]  D. Vu,et al.  Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[50]  P. Raskin,et al.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. , 2001, Diabetes care.

[51]  K. Vollebregt,et al.  Comparison of OPS imaging and conventional capillary microscopy to study the human microcirculation. , 2001, Journal of applied physiology.

[52]  W. Mutschler,et al.  Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. , 2001, Resuscitation.

[53]  D. Yamada,et al.  The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. , 2001, Diabetes care.

[54]  T. Mussack,et al.  S-100b, sE-selectin, and sP-selectin for Evaluation of Hypoxic Brain Damage in Patients after Cardiopulmonary Resuscitation: Pilot Study , 2001, World Journal of Surgery.

[55]  P. Whelton,et al.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.

[56]  S. J. Lloyd,et al.  Pulmonary Edema Associated with Rosiglitazone and Troglitazone , 2001, The Annals of pharmacotherapy.

[57]  S. Oparil,et al.  Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. , 2000, The American journal of cardiology.

[58]  C. Rubin,et al.  Echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone , 2000 .

[59]  Klaus P. Ebmeier,et al.  Memory impairment in out-of-hospital cardiac arrest survivors is associated with global reduction in brain volume, not focal hippocampal injury. , 2000, Stroke.

[60]  B. Howard,et al.  Impact of diabetes on cardiac structure and function: the strong heart study. , 2000, Circulation.

[61]  D. Eizirik,et al.  Interleukin-1beta-induced alteration in a beta-cell phenotype can reduce cellular sensitivity to conditions that cause necrosis but not to cytokine-induced apoptosis. , 2000, Diabetes.

[62]  O. Kemmotsu,et al.  Out-of-hospital cardiac arrest increases soluble vascular endothelial adhesion molecules and neutrophil elastase associated with endothelial injury , 2000, Intensive Care Medicine.

[63]  G. Teasdale,et al.  Glasgow Head Injury Outcome Prediction Program: an independent assessment , 1999, Journal of neurology, neurosurgery, and psychiatry.

[64]  O. Kemmotsu,et al.  Tissue factor and tissue factor pathway inhibitor levels during and after cardiopulmonary resuscitation. , 1999, Thrombosis research.

[65]  W. A. Murray,et al.  Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. , 1999, The New England journal of medicine.

[66]  M. Kodama,et al.  Troglitazone inhibits bicarbonate secretion in rat and human duodenum. , 1999, The Journal of pharmacology and experimental therapeutics.

[67]  I. Hirsch,et al.  Pulmonary edema associated with troglitazone therapy. , 1999, Archives of internal medicine.

[68]  P. Dogterom,et al.  Rosiglitazone: No Effect on Erythropoiesis or Premature Red Cell Destruction , 1999 .

[69]  P. Richman,et al.  The etiology of cardiac arrest in children and young adults: special considerations for ED management. , 1999, The American journal of emergency medicine.

[70]  L. Squassante,et al.  Troglitazone has no effect on red cell mass or other erythropoietic parameters , 1999, European Journal of Clinical Pharmacology.

[71]  Y. Bando,et al.  Troglitazone Combination Therapy in Obese Type 2 Diabetic Patients Poorly Controlled with α-Glucosidase Inhibitors , 1999, The Journal of international medical research.

[72]  M. Shimoyama,et al.  Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. , 1999, Diabetes.

[73]  A Laupacis,et al.  What is the quality of life for survivors of cardiac arrest? A prospective study. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[74]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[75]  下山晶樹 Hemodynamic Basis for the Acute Cardiac Effects of Troglitazone in Isolated Perfused Rat Hearts(ラット摘出潅流心におけるトログリタゾン投与時の心血行動態に対する急性効果) , 1999 .

[76]  C. Stoutenbeek,et al.  Systematic review of early prediction of poor outcome in anoxicischaemic coma , 1998, The Lancet.

[77]  C. Clancy,et al.  Outcomes Research: Measuring the End Results of Health Care , 1998, Science.

[78]  N. Sato,et al.  Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients , 1998, Diabetes Care.

[79]  G. Williams,et al.  Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. , 1998, Diabetes.

[80]  M. Holzer,et al.  The influence of chronic prearrest health conditions on mortality and functional neurological recovery in cardiac arrest survivors. , 1998, The American journal of medicine.

[81]  S. Zarich,et al.  Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. , 1998, Circulation.

[82]  T. Yoshimoto,et al.  Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. , 1997, The American journal of physiology.

[83]  J P Ornato,et al.  Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital 'Utstein style'. A statement for healthcare professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Aus , 1997, Resuscitation.

[84]  G. Lopaschuk,et al.  Diabetes mellitus and the cardiovascular system. , 1997, Cardiovascular research.

[85]  F. Sterz,et al.  Blood Glucose Concentration after Cardiopulmonary Resuscitation Influences Functional Neurological Recovery in Human Cardiac Arrest Survivors , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[86]  M. Ghazzi,et al.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. , 1997 .

[87]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[88]  M. Callaham,et al.  Survivors of Out-of-Hospital Cardiac Arrest Correlates Poorly With Traditional Neurologic Outcome Scales , 1996 .

[89]  N L Geller,et al.  Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. , 1996, Stroke.

[90]  K. Fox,et al.  Resuscitation from out-of-hospital cardiac arrest: implications for cardiac enzyme estimation. , 1996, Resuscitation.

[91]  M. Elliott Interrater reliability of the Glasgow Coma Scale. , 1996, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[92]  R. Berg,et al.  Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. , 1996, Journal of the American College of Cardiology.

[93]  W. Young,et al.  Continuous time estimation as a behavioural index of human cerebral ischaemia during temporary occlusion of the internal carotid artery. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[94]  D. Simonson,et al.  Assessment of quality-of-life outcomes. , 1996, The New England journal of medicine.

[95]  J. Walker,et al.  Factors associated with cognitive recovery after cardiopulmonary resuscitation. , 1996, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[96]  L. Sayadi,et al.  Abstract , 1897, Journal of the Neurological Sciences.

[97]  P. Nawroth,et al.  Activation of blood coagulation after cardiac arrest is not balanced adequately by activation of endogenous fibrinolysis. , 1995, Circulation.

[98]  D. Warner Intravenous glucose after out-of-hospital cardiopulmonary arrest: A community-based randomized trial. , 1994 .

[99]  S. Kelsey,et al.  Assessment of neurological prognosis in comatose survivors of cardiac arrest , 1994, The Lancet.

[100]  C. Dougherty,et al.  Longitudinal recovery following sudden cardiac arrest and internal cardioverter defibrillator implantation: survivors and their families. , 1994, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[101]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[102]  M. Kaste,et al.  Neuropsychological sequelae of cardiac arrest. , 1993, JAMA.

[103]  C. Barton,et al.  A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. , 1992, JAMA.

[104]  P. Pepe,et al.  A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. , 1992, The New England journal of medicine.

[105]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[106]  H. Rifkin,et al.  Ellenberg and Rifkinʼs Diabetes Mellitus: Theory and Practice , 1992 .

[107]  N. Taub,et al.  Assessment of Scales of Disability and Handicap for Stroke Patients , 1991, Stroke.

[108]  H. Stopfkuchen [Cardiopulmonary resuscitation in children]. , 1991, Krankenpflege Journal.

[109]  T. J. Appleton,et al.  The effect of standard- and high-dose epinephrine on coronary perfusion pressure during prolonged cardiopulmonary resuscitation. , 1991, JAMA.

[110]  R. Murden,et al.  Mini‐Mental State Exam Scores Vary with Education in Blacks and Whites , 1991, Journal of the American Geriatrics Society.

[111]  M. Kaste,et al.  Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. , 1990, JAMA.

[112]  M. Jastremski,et al.  Glucocorticoid treatment does not improve neurological recovery following cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. , 1989, JAMA.

[113]  J. Marler,et al.  Measurements of acute cerebral infarction: a clinical examination scale. , 1989, Stroke.

[114]  T Brott,et al.  Measurements of acute cerebral infarction: lesion size by computed tomography. , 1989, Stroke.

[115]  B Cooper,et al.  Improving the sensitivity of the Barthel Index for stroke rehabilitation. , 1989, Journal of clinical epidemiology.

[116]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[117]  R J Myerburg,et al.  Epidemiology of Ventricular Tachycardia/Ventricular Fibrillation and Sudden Cardiac Death , 1986, Pacing and clinical electrophysiology : PACE.

[118]  J. Ornato,et al.  Rapid change in pulmonary vascular hemodynamics with pulmonary edema during cardiopulmonary resuscitation. , 1985, The American journal of emergency medicine.

[119]  D L McGee,et al.  Epidemiology of sudden death: insights from the Framingham Study. , 1985, Cardiovascular clinics.

[120]  G. Reeder Heart Disease: A Textbook of Cardiovascular Medicine , 1984 .

[121]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[122]  B Jennett,et al.  Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. , 1981, Journal of neurology, neurosurgery, and psychiatry.

[123]  B Jennett,et al.  Assessment of outcome after severe brain damage. , 1975, Lancet.

[124]  B. Jennett,et al.  Assessment of coma and impaired consciousness. A practical scale. , 1974, Lancet.

[125]  F. Mahoney,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.